Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man.

Authors:
Maren Luchtefeld, Heribert Schunkert, Monika Stoll, Tina Selle, Rachel Lorier, Karsten Grote, Christian Sagebiel, Kumaravelu Jagavelu, Uwe J F Tietge, Ulrike Assmus, Konrad Streetz, Christian Hengstenberg, Marcus Fischer, Björn Mayer, Karen Maresso, Nour Eddine El Mokhtari, Stefan Schreiber, Werner Müller, Udo Bavendiek, Christina Grothusen, Helmut Drexler, Christian Trautwein, Ulrich Broeckel, Bernhard Schieffer
Year of publication:
2007
Volume:
204
Issue:
8
Issn:
0022-1007
Journal title abbreviated:
J EXP MED
Journal title long:
The journal of experimental medicine
Impact factor:
11.240
Abstract: 
Liver-derived acute phase proteins (APPs) emerged as powerful predictors of cardiovascular disease and cardiovascular events, but their functional role in atherosclerosis remains enigmatic. We report that the gp130 receptor, which is a key component of the inflammatory signaling pathway within hepatocytes, influences the risk of atherosclerosis in a hepatocyte-specific gp130 knockout. Mice on an atherosclerosis-prone genetic background exhibit less aortic atherosclerosis (P < 0.05) with decreased plaque macrophages (P < 0.01). Translating these findings into humans, we show that genetic variation within the human gp130 homologue, interleukin 6 signal transducer (IL6ST), is significantly associated with coronary artery disease (CAD; P < 0.05). We further show a significant association of atherosclerotic disease at the ostium of the coronary arteries (P < 0.005) as a clinically important and heritable subphenotype in a large sample of families with myocardial infarction (MI) and a second independent population-based cohort. Our results reveal a central role of a hepatocyte-specific, gp130-dependent acute phase reaction for plaque development in a murine model of atherosclerosis, and further implicate IL6ST as a genetic susceptibility factor for CAD and MI in humans. Thus, the acute phase reaction should be considered an important target for future drug development in the management of CAD.